Oric Pharmaceuticals (ORIC) Baird Global Healthcare Conference 2025 summary

Pipeline and strategic focus

• Focused on overcoming resistance in cancer, with lead programs in prostate and lung cancer targeting solid tumors.

• ORIC-944 (PRC2 inhibitor) for prostate cancer and ORIC-114 for lung cancer are both in dose optimization, aiming for phase 3 starts next year.

• Strong financial position with cash runway extending beyond phase 3 data readouts for both programs.

ORIC-944 prostate cancer program

• ORIC-944 targets the EED subunit of PRC2, aiming to overcome resistance seen with EZH2 inhibitors.

• Demonstrated improved potency, longer half-life (20 hours), and favorable safety compared to competitors like Pfizer's Mevrometostat.

• Early data showed higher PSA50 (47%) and PSA90 (24%) response rates versus Pfizer's comparator, with less severe toxicity and no alopecia.

• Dose optimization ongoing, with phase 3 dose selection expected by early next year and pivotal study launch in the first half of next year.

• Upcoming data updates in late 2024 and Q1 2026 will provide further efficacy, ctDNA, and early durability data.

ORIC-114 lung cancer program

• ORIC-114 is being developed for multiple lung cancer populations, focusing on safety, tolerability, and CNS activity.

• Substantial data readouts expected in late 2024 and early 2025 across three patient cohorts, including those with active brain metastases.

• Recently secured a supply agreement with J&J for amivantamab, enabling a differentiated combination approach in first-line EGFR exon 20 patients.

• Pivotal study for ORIC-114 planned to start next year, with go/no-go decisions based on upcoming data benchmarks.